%0 Journal Article %J J Alzheimers Dis %D 2018 %T Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease. %A Tsou, Han-Hsing %A Hsu, Wen-Chin %A Fuh, Jong-Ling %A Chen, Shih-Pin %A Liu, Tsung-Yun %A Wang, Hsiang-Tsui %K Acetylcysteine %K Acrolein %K Aged %K Aged, 80 and over %K Alzheimer Disease %K Biomarkers %K Case-Control Studies %K Creatinine %K Disease Progression %K Early Diagnosis %K Female %K Humans %K Male %K Middle Aged %X

Alzheimer's disease (AD) is a detrimental neurodegenerative disease, and early diagnosis appears to be the key to successful treatment. Acrolein, a byproduct of lipid peroxidation, has been shown to contribute to the pathological process of AD. This study recruited 118 elderly subjects consisting of 58 non-demented control subjects and 62 AD patients. We analyzed the acrolein-related metabolites in the plasma, cerebrospinal fluid (CSF), and urine of all subjects. We found that the levels of acrolein-conjugated protein (Acr-PC) in the plasma (p = 0.00012) and CSF (p = 0.00161) of AD patients were significantly higher than those of control subjects, whereas the levels of a urinary acrolein metabolite, 3-hydroxypropyl mercapturic acid (3-HPMA), were markedly decreased (p = 0.00882) in AD patients. These data suggest that deregulated acrolein metabolism may be correlated with neuronal damage in AD patients, which might provide further insights into the disease progression and early diagnosis of AD.

%B J Alzheimers Dis %V 61 %P 571-580 %8 2018 %G eng %N 2 %1 http://www.ncbi.nlm.nih.gov/pubmed/29226874?dopt=Abstract %R 10.3233/JAD-170736